-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on February 23rd.
The
fourth batch of national centralized procurement won the bid results, and the fourth batch of national procurement will be officially launched
.
The implementation notice came on February 22.
Jiangxi Provincial Medical Insurance Bureau issued the "Regarding the implementation of the fourth batch of nationally organized centralized drug procurement The "Notice on Procurement of Related Drugs on the Internet" specifies the implementation work arrangements for the fourth batch of national procurement results
.
The notice requires that the selected drugs in Jiangxi area need to fill in the online information and confirm the distribution relationship, and the non-selected drugs in Jiangxi area need to fill in the information and price declaration online.
The price declaration requirements are as follows: As the dust settles on the results of the fourth batch of national centralized procurement, its Implementation is the focus of the industry's attention
.
With the advancement of centralized procurement, it is believed that various provinces will soon start the application of net-linked varieties
.
The implementation of the results of the fourth batch of national centralized procurement has also been put on the agenda
.
The list and prices of the fourth batch of nationally sourced varieties supplied in Jiangxi:
Medical representative, how are you?
Although the bargaining power of the fourth batch of national sourcing has not diminished, with the experience of previous collective sourcing, the market performance of this centralized sourcing seems to be more calm
.
If the over-rated drugs get the admission ticket for centralized procurement, they will either take the initiative to greatly reduce the price and participate deeply, or give up on the initiative like a foreign-funded pharmaceutical company with sufficient strength
.
After several batches of centralized procurement by countries and uninterrupted local centralized procurement, in the process of continuing to be tested, the reaction of the entire market due to centralized procurement has gradually become accustomed
.
It is understood that the fourth batch of national centralized procurement has a total of 158 products.
The average price drop of the proposed selection reached 52%, and the highest drop reached 96%.
Preliminary estimates are expected to save 12.
4 billion yuan in medicine costs a year
.
In other words, with the market shrinking substantially and the price of medicines hitting the floor, a major reshuffle closely related to medical representatives has already arrived
.
Especially in the special period at the beginning of the new year, I believe many medical representatives are considering re-planning their work
.
Recently, there has also been a lot of news about the performance indicators of various divisions in the industry in the new year.
Some have cancelled the indicator assessment, some have lowered the indicator, and more are actually the indicator rise
.
For those medical representatives who are engaged in the varieties related to national procurement, the pressure is even greater
.
Judging from the companies thathave won the bid, large-scale pharmaceutical companies with strong R&D capabilities have many shortlisted products
.
According to statistics from Cyberlan, four batches of national centralized procurement have been carried out.
Many domestic pharmaceutical companies have emerged from them.
A total of more than 10 varieties have been successfully selected.
Among them, as many as 23 varieties of Qilu Pharmaceutical have been selected in the four batches of national centralized procurement.
.
Most of these pharmaceutical companies are leading domestic innovative drug companies, with an annual R&D investment of 2 to 4 billion yuan, and many generic drugs have successfully passed the consistency evaluation
.
For the first four batches of national procurement, the substantial price cuts of medicines are just a landing of the results of the selection, but for medical representatives, it is actually just the beginning.
.
It is not necessarily a good thing to be a medical representative whether the country chooses to be selected or not to be selected
.
Judging from the current price reduction situation, many drugs have been reduced by more than 90%, and their profit margins have been reduced to the extreme.
They will not be able to afford clinical promotion, related product line team adjustments, and even the possibility of abolishing teams
.
However, if the products that are not responsible enter the centralized procurement of the country, the relevant pharmaceutical representatives will face unemployment, and the iron will still depend on their own hard work.
There are still many opportunities in the market waiting for everyone to explore
.
Prior to this, senior executives of relevant pharmaceutical companies told Cyberland that national procurement has actually accelerated the flow of talents in the pharmaceutical market
.
When some pharmaceutical companies were laying off employees last year, their companies formed a team of 200 people
.
In fact, as the country vigorously encourages the development of innovative drugs, the promotion of innovative drugs is the key direction of the development of pharmaceutical representatives
.
If it can help companies promote clinical research on new drugs, so that doctors can obtain more and more timely new drug information, and benefit more patients, such medical representatives will always be needed by the industry
.
The
fourth batch of national centralized procurement won the bid results, and the fourth batch of national procurement will be officially launched
.
The implementation notice came on February 22.
Jiangxi Provincial Medical Insurance Bureau issued the "Regarding the implementation of the fourth batch of nationally organized centralized drug procurement The "Notice on Procurement of Related Drugs on the Internet" specifies the implementation work arrangements for the fourth batch of national procurement results
.
The notice requires that the selected drugs in Jiangxi area need to fill in the online information and confirm the distribution relationship, and the non-selected drugs in Jiangxi area need to fill in the information and price declaration online.
The price declaration requirements are as follows: As the dust settles on the results of the fourth batch of national centralized procurement, its Implementation is the focus of the industry's attention
.
With the advancement of centralized procurement, it is believed that various provinces will soon start the application of net-linked varieties
.
The implementation of the results of the fourth batch of national centralized procurement has also been put on the agenda
.
The list and prices of the fourth batch of nationally sourced varieties supplied in Jiangxi:
Serial number | Generic name of the drug | Dosage form | specification | Packing quantity | sales unit | Selected enterprise | Selected price (yuan) |
---|---|---|---|---|---|---|---|
1 | Esomeprazole magnesium enteric-coated capsules | Capsules | 20mg | 30 capsules/bottle×1 bottle/box | box | Zhengda Tianqing Pharmaceutical Group Co. , Ltd. | 87. 43 |
2 | Esomeprazole magnesium enteric-coated capsules | Capsules | 40mg | 30 capsules/bottle×1 bottle/box | box | Zhengda Tianqing Pharmaceutical Group Co. , Ltd. | 148. 63 |
3 | Amisulpride tablets | tablet | 0. 1g | 10pcs/board×3board/box | box | Shenzhen Fangu Pharmaceutical Co. , Ltd. (Xiamen Lizhuo Pharmaceutical Co. , Ltd. is commissioned to produce) | 37. 56 |
4 | Amisulpride tablets | tablet | 0. 2g | 10pcs/board×2board/box | box | Shenzhen Fangu Pharmaceutical Co. , Ltd. (Xiamen Lizhuo Pharmaceutical Co. , Ltd. is commissioned to produce) | 43. 2 |
5 | Ambroxol Hydrochloride Injection | injection | 1ml:7. 5mg | 10pcs/box | box | Shandong Luoxin Pharmaceutical Group Co. , Ltd. | 3. 35 |
6 | Ambroxol Hydrochloride Injection | injection | 2ml: 15mg | 10pcs/box | box | Shandong Luoxin Pharmaceutical Group Co. , Ltd. | 5. 7 |
7 | Ambroxol Hydrochloride Injection | injection | 4ml: 30mg | 5 pcs/box | box | Shandong Luoxin Pharmaceutical Group Co. , Ltd. | 4. 85 |
8 | Olopatadine Hydrochloride Eye Drops | Ophthalmic preparations | 5ml:5mg (0. 1%) | 1 bottle/box | box | Zhejiang Jianfeng Pharmaceutical Co. , Ltd. | 19. 9 |
9 | Pyrazinamide tablets | tablet | 0. 25g | 100 tablets/bottle | bottle | Shenyang Hongqi Pharmaceutical Co. , Ltd. | 19. 49 |
10 | Propofol Medium/Long Chain Fat Emulsion Injection | injection | 20ml:0. 2g | 5 pcs/box | box | Sichuan Kelun Pharmaceutical Co. , Ltd. | 74. 29 |
11 | Ibuprofen tablets | tablet | 0. 1g | 100 tablets/bottle | bottle | Qingdao Huanghai Pharmaceutical Co. , Ltd. | 15. 2 |
12 | Ibuprofen injection | injection | 4ml: 0. 4g | 6 pcs/box | box | Hangzhou Minsheng Pharmaceutical Co. , Ltd. | 82. 68 |
13 | Ibuprofen injection | injection | 8ml: 0. 8g | 5 pcs/box | box | Hangzhou Minsheng Pharmaceutical Co. , Ltd. | 117. 13 |
14 | Duloxetine Hydrochloride Enteric-coated Capsules | Capsules | 20mg | 60 capsules/bottle/box | box | Dongguan Yangzhikang Pharmaceutical Co. , Ltd. (manufactured by Guangdong Dongyang Sunshine Pharmaceutical Co. , Ltd. ) | 33. 6 |
15 | Doxofylline Injection | injection | 10ml:0. 1g | 6 per box | box | Zhejiang Beisheng Pharmaceutical Hansheng Pharmaceutical Co. , Ltd. | 77. 97 |
16 | Doxofylline Injection | injection | 20ml:0. 2g | 2 per box | box | Zhejiang Beisheng Pharmaceutical Hansheng Pharmaceutical Co. , Ltd. | 44. 18 |
17 | Engligliflozin | tablet | 10mg | 10pcs/board×3board/box | box | Zhengda Tianqing Pharmaceutical Group Co. , Ltd. | 55. 64 |
18 | Engligliflozin | tablet | 25mg | 10pcs/board×3board/box | box | Zhengda Tianqing Pharmaceutical Group Co. , Ltd. | 112. 21 |
Serial number | Generic name of the drug | Dosage form | specification | Packing quantity | sales unit | Selected enterprise | Selected price (yuan) |
19 | Emtricitabine Tenofovir Tablets | tablet | Emtricitabine 200mg+ Tenofovir Disoproxil fumarate 300mg | 10 pieces/board×1board/bag×1bag/box | box | Haisco Pharmaceutical (Meishan) Co. , Ltd. | 220 |
20 | Gliclazide sustained-release tablets | tablet | 30mg | 15pcs/board×4board/box | box | Tianjin Junan Biopharmaceutical Co. , Ltd. | 36. 56 |
twenty one | Gabapentin Capsules | Capsules | 0. 1g | 10 tablets per board, 5 boards per bag, 1 bag per box | box | Jiangsu Hengrui Pharmaceutical Co. , Ltd. | 6 |
twenty two | Gabapentin Capsules | Capsules | 0. 3g | 10 tablets per board, 1 board per bag, 1 bag per box | box | Jiangsu Hengrui Pharmaceutical Co. , Ltd. | 2. 95 |
twenty three | Canagliflozin | tablet | 0. 1g | 7pcs/board×2board/box | box | Jiangsu Haosen Pharmaceutical Group Co. , Ltd. | 25. 38 |
twenty four | Canagliflozin | tablet | 0. 1g | 7pcs/board×1board/box | box | Jiangsu Haosen Pharmaceutical Group Co. , Ltd. | 13. 02 |
25 | Canagliflozin | tablet | 0. 3g | 7pcs/board×1board/box | box | Jiangsu Haosen Pharmaceutical Group Co. , Ltd. | 30. 18 |
26 | Quetiapine Fumarate Sustained Release Tablets | tablet | 200mg | 2×10 pieces/board/box | box | Beijing Tianheng Pharmaceutical Research Institute Nanyang Tianheng Pharmaceutical Factory | 67. 8 |
27 | Loxoprofen sodium tablets | tablet | 60mg | 12 pieces/board, 3 boards per package, 1 package per box | box | Disa Pharmaceutical Group Co. , Ltd. | 10. 48 |
28 | Loxoprofen sodium tablets | tablet | 60mg | 12 pieces/board, 4 boards per package, 1 package per box | box | Disa Pharmaceutical Group Co. , Ltd. | 13. 83 |
29 | Loratadine Tablets | tablet | 10mg | 10pcs/board×1board/box | box | Wonder Pharmaceutical (Hainan) Co. , Ltd. | 8. 28 |
30 | Mosapride Citrate Tablets | tablet | 5mg | 36 pieces/box | box | Lunanbeite Pharmaceutical Co. , Ltd. | 21. 69 |
31 | Nateglinide tablets | tablet | 120mg | 10pcs/board×3board/box | box | Jiangsu Deyuan Pharmaceutical Co. , Ltd. | 29. 38 |
32 | Nateglinide tablets | tablet | 120mg | 60 tablets/bottle/box | box | Jiangsu Deyuan Pharmaceutical Co. , Ltd. | 57. 29 |
33 | Parecoxib Sodium for Injection | injection | 40mg | 10 bottles/box | box | Nanjing Shenghe Pharmaceutical Co. , Ltd. | 51 |
34 | Pantoprazole sodium enteric-coated tablets | tablet | 40mg | 14pcs/board×2board/box | box | Hunan Jiudian Pharmaceutical Co. , Ltd. | 23. 16 |
35 | Pantoprazole Sodium for Injection | injection | 40mg | 5 pcs/box | box | Chengdu Tongde Pharmaceutical Co. , Ltd. | 14. 2 |
36 | Perindopril tert-butylamine tablets | tablet | 4mg | 7 pieces/board×3 boards/bag×1bag/box | box | Haisco Pharmaceutical (Meishan) Co. , Ltd. | 15. 12 |
37 | Bortezomib for Injection | injection | 1mg | 1 bottle/box | bottle | Jiangsu Haosen Pharmaceutical Group Co. , Ltd. | 600 |
38 | Bortezomib for Injection | injection | 3. 5mg | 1 bottle/box | bottle | Jiangsu Haosen Pharmaceutical Group Co. , Ltd. | 1565. 5 |
39 | Pramipexole Hydrochloride Sustained Release Tablets | tablet | 0. 375mg | 10 pieces per board, 1 board per box | box | Jiangsu Hengrui Pharmaceutical Co. , Ltd. | 29. 53 |
40 | Pramipexole Hydrochloride Sustained Release Tablets | tablet | 0. 75mg | 10 pieces per board, 1 board per box | box | Jiangsu Hengrui Pharmaceutical Co. , Ltd. | 50. 2 |
41 | Pramipexole hydrochloride tablets | tablet | 0. 25mg | 10 pieces/board×1 board/bag, 3 bags/box | box | Qilu Pharmaceutical (Hainan) Co. , Ltd. | 11. 4 |
Serial number | Generic name of the drug | Dosage form | specification | Packing quantity | sales unit | Selected enterprise | Selected price (yuan) |
42 | Pramipexole hydrochloride tablets | tablet | 1mg | 7 pieces/board×1 board/bag, 4 bags/box | box | Qilu Pharmaceutical (Hainan) Co. , Ltd. | 30. 83 |
43 | Pregabalin Capsules | Capsules | 75mg | 8 tablets/plate×1 version/box | box | Ningbo Kerkang Minuohua Pharmaceutical Co. , Ltd. (Ningbo Minova Tiankang Pharmaceutical Co. , Ltd. is commissioned to produce) | 18. 9 |
44 | Pregabalin Capsules | Capsules | 150mg | 8 tablets/plate×1 version/box | box | Ningbo Kerkang Minuohua Pharmaceutical Co. , Ltd. (Ningbo Minova Tiankang Pharmaceutical Co. , Ltd. is commissioned to produce) | 32. 13 |
45 | Calcium Dobesilate Tablets | tablet | 0. 5g | 10pcs/board×3board/box | box | Nanjing Chang'ao Pharmaceutical Co. , Ltd. | 22. 5 |
46 | Repaglinide Tablets | tablet | 0. 5mg | 15pcs/board×4board/box | box | Beijing Fuyuan Pharmaceutical Co. , Ltd. | 8. 24 |
47 | Repaglinide Tablets | tablet | 1mg | 15pcs/board×2board/box | box | Beijing Fuyuan Pharmaceutical Co. , Ltd. | 7. 18 |
48 | Sorafenib tosylate tablets | tablet | 0. 2g | 10 pieces/board×6 boards/box | box | Jiangxi Shanxiang Pharmaceutical Co. , Ltd. | 1369 |
49 | Sorafenib tosylate tablets | tablet | 0. 2g | 10 pieces/board×12 boards/box | box | Jiangxi Shanxiang Pharmaceutical Co. , Ltd. | 2,669. 55 |
50 | Ticagrelor tablets | tablet | 60mg | 14pcs/board×1board/box | box | Nanjing Zhengda Tianqing Pharmaceutical Co. , Ltd. | 12. 88 |
51 | Telmisartan tablets | tablet | 40mg | 7pcs/board×4board/box | box | Beijing Fuyuan Pharmaceutical Co. , Ltd. | 12. 89 |
52 | Telmisartan tablets | tablet | 80mg | 7pcs/board×2board/box | box | Beijing Fuyuan Pharmaceutical Co. , Ltd. | 11. 24 |
53 | Temozolomide Capsules | Capsules | 20mg | 5 capsules/bottle | bottle | Jiangsu Tasly Diyi Pharmaceutical Co. , Ltd. | 261. 06 |
54 | Temozolomide Capsules | Capsules | 50mg | 7 capsules/bottle | bottle | Jiangsu Tasly Diyi Pharmaceutical Co. , Ltd. | 728. 06 |
55 | Temozolomide Capsules | Capsules | 100mg | 5 capsules/bottle | bottle | Jiangsu Tasly Diyi Pharmaceutical Co. , Ltd. | 895 |
56 | Salbutamol Sulfate Solution for Inhalation | Inhalant | 5mg/2. 5ml | 10pcs/box | box | Zhejiang Furuixi Pharmaceutical Co. , Ltd. | 22. 88 |
57 | Valsartan and Amlodipine Tablets (Ⅰ) | tablet | Valsartan 80mg+ Amlodipine 5mg | 7pcs/board×1board/box | box | Jiangsu Hengrui Pharmaceutical Co. , Ltd. | 9. 72 |
58 | Valsartan Hydrochlorothiazide Tablets | tablet | Valsartan 80mg + hydrochlorothiazide 12. 5mg | 14 pieces per board, 1 board per box | box | China Resources SECCO Pharmaceutical Co. , Ltd. | 25. 2 |
59 | Valsartan Hydrochlorothiazide Tablets | tablet | Valsartan 80mg + hydrochlorothiazide 12. 5mg | 14 pieces per board, 2 boards per box | box | China Resources SECCO Pharmaceutical Co. , Ltd. | 49. 14 |
60 | Voriconazole tablets | tablet | 200mg | 30 pieces/box | box | HEXAL AG (Sandoz Private Limited) | 1044 |
61 | Norfloxacin Tablets | tablet | 0. 1g | 10pcs/board×3board/box | box | Zhejiang Pharmaceutical Co. , Ltd. (produced by Xinchang Pharmaceutical Factory of Zhejiang Pharmaceutical Co. , Ltd. ) | 12. 13 |
62 | Terbinafine Hydrochloride Tablets | tablet | 0. 125g | 14 pieces/box | box | Qilu Pharmaceutical Co. , Ltd. | 6. 44 |
63 | Cefprozil Tablets | tablet | 0. 25g | 12pcs/board×1board/box | box | Nanjing Yihua Pharmaceutical Co. , Ltd. | 8. 95 |
Serial number | Generic name of the drug | Dosage form | specification | Packing quantity | sales unit | Selected enterprise | Selected price (yuan) |
64 | Levofloxacin Tablets | tablet | 0. 25g | 10 pieces/board, 3 boards/box | box | Zhejiang Puli Pharmaceutical Co. , Ltd. | 13. 88 |
65 | Sodium Hyaluronate Eye Drops | Eye drops | 10ml: 10mg (0. 1%) | 10ml per bottle, 1 bottle per box | box | Zhongshan Wanhan Pharmaceutical Co. , Ltd. | 13. 38 |
66 | Sodium Hyaluronate Eye Drops | Eye drops | 0. 4ml:1. 2mg (0. 3%) | 24 per box | box | Yangtze River Pharmaceutical Group Co. , Ltd. | 50. 4 |
67 | Bivarudine for Injection | injection | 0. 25g | 1 bottle/box | bottle | Hainan Shuangcheng Pharmaceutical Co. , Ltd. | 777. 5 |
Medical representative, how are you?
Although the bargaining power of the fourth batch of national sourcing has not diminished, with the experience of previous collective sourcing, the market performance of this centralized sourcing seems to be more calm
.
If the over-rated drugs get the admission ticket for centralized procurement, they will either take the initiative to greatly reduce the price and participate deeply, or give up on the initiative like a foreign-funded pharmaceutical company with sufficient strength
.
After several batches of centralized procurement by countries and uninterrupted local centralized procurement, in the process of continuing to be tested, the reaction of the entire market due to centralized procurement has gradually become accustomed
.
It is understood that the fourth batch of national centralized procurement has a total of 158 products.
The average price drop of the proposed selection reached 52%, and the highest drop reached 96%.
Preliminary estimates are expected to save 12.
4 billion yuan in medicine costs a year
.
In other words, with the market shrinking substantially and the price of medicines hitting the floor, a major reshuffle closely related to medical representatives has already arrived
.
Especially in the special period at the beginning of the new year, I believe many medical representatives are considering re-planning their work
.
Recently, there has also been a lot of news about the performance indicators of various divisions in the industry in the new year.
Some have cancelled the indicator assessment, some have lowered the indicator, and more are actually the indicator rise
.
For those medical representatives who are engaged in the varieties related to national procurement, the pressure is even greater
.
Judging from the companies thathave won the bid, large-scale pharmaceutical companies with strong R&D capabilities have many shortlisted products
.
According to statistics from Cyberlan, four batches of national centralized procurement have been carried out.
Many domestic pharmaceutical companies have emerged from them.
A total of more than 10 varieties have been successfully selected.
Among them, as many as 23 varieties of Qilu Pharmaceutical have been selected in the four batches of national centralized procurement.
.
Most of these pharmaceutical companies are leading domestic innovative drug companies, with an annual R&D investment of 2 to 4 billion yuan, and many generic drugs have successfully passed the consistency evaluation
.
For the first four batches of national procurement, the substantial price cuts of medicines are just a landing of the results of the selection, but for medical representatives, it is actually just the beginning.
.
It is not necessarily a good thing to be a medical representative whether the country chooses to be selected or not to be selected
.
Judging from the current price reduction situation, many drugs have been reduced by more than 90%, and their profit margins have been reduced to the extreme.
They will not be able to afford clinical promotion, related product line team adjustments, and even the possibility of abolishing teams
.
However, if the products that are not responsible enter the centralized procurement of the country, the relevant pharmaceutical representatives will face unemployment, and the iron will still depend on their own hard work.
There are still many opportunities in the market waiting for everyone to explore
.
Prior to this, senior executives of relevant pharmaceutical companies told Cyberland that national procurement has actually accelerated the flow of talents in the pharmaceutical market
.
When some pharmaceutical companies were laying off employees last year, their companies formed a team of 200 people
.
In fact, as the country vigorously encourages the development of innovative drugs, the promotion of innovative drugs is the key direction of the development of pharmaceutical representatives
.
If it can help companies promote clinical research on new drugs, so that doctors can obtain more and more timely new drug information, and benefit more patients, such medical representatives will always be needed by the industry
.